Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 6.52 USD -2.4% Market Closed
Updated: May 28, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

400.7m
-21%
Assets
Growth Rates:
1 Year
+17%
3 Years
+91%
5 Years
+92%
7 Years
+32%
10 Years
-
1.1B
+0.1%
Liabilities
Growth Rates:
1 Year
+25%
3 Years
+176%
5 Years
+2 598%
7 Years
+4 219%
10 Years
-
-692m
-18%
Equity
Growth Rates:
1 Year
-31%
3 Years
-272%
5 Years
-
7 Years
-
10 Years
-

Balance Sheet Decomposition
Immunitybio Inc

400.7m
Assets
1.1B
Liabilities
400.7m
Assets
1.1B
Liabilities
Current Assets 195.7m
Cash & Short-Term Investments 170.5m
Receivables 2.1m
Other Current Assets 23.1m
Non-Current Assets 205m
PP&E 178.8m
Intangibles 16.6m
Other Non-Current Assets 9.6m
Current Liabilities 53.8m
Accounts Payable 13.9m
Accrued Liabilities 38.2m
Other Current Liabilities 1.7m
Non-Current Liabilities 1B
Long-Term Debt 850.5m
Other Non-Current Liabilities 188.4m

Balance Sheet
Immunitybio Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
59
176
8
24
17
16
35
181
105
265
Cash Equivalents
59
176
8
24
17
16
35
181
105
265
Short-Term Investments
0
118
191
104
58
36
61
136
3
1
Total Receivables
0
2
3
1
11
0
5
1
2
3
Accounts Receivables
0
0
0
0
0
0
0
0
0
0
Other Receivables
0
2
0
0
0
0
5
0
0
0
Other Current Assets
0
2
4
3
3
4
11
16
32
24
Total Current Assets
59
298
205
133
89
56
112
334
141
294
PP&E Net
0
7
19
77
77
72
91
119
190
183
PP&E Gross
0
7
19
77
77
72
91
119
190
183
Accumulated Depreciation
0
0
1
4
12
19
42
53
69
84
Intangible Assets
0
7
5
3
1
0
2
1
20
17
Note Receivable
0
0
0
0
0
0
7
6
7
7
Long-Term Investments
0
55
88
38
14
11
9
1
1
1
Other Long-Term Assets
0
0
0
0
2
4
2
7
5
3
Total Assets
60
N/A
367
+511%
318
-13%
250
-21%
182
-27%
143
-21%
221
+55%
469
+112%
362
-23%
504
+39%
Liabilities
Accounts Payable
1
2
4
6
3
2
12
11
21
9
Accrued Liabilities
0
3
6
11
21
9
39
54
43
46
Short-Term Debt
0
0
0
0
0
0
0
299
432
0
Current Portion of Long-Term Debt
0
0
0
0
1
1
16
0
1
1
Other Current Liabilities
0
2
3
4
2
1
2
4
4
1
Total Current Liabilities
2
6
13
21
27
12
68
369
501
58
Long-Term Debt
0
0
2
2
6
0
254
306
241
837
Deferred Income Tax
0
1
1
1
0
0
0
0
0
0
Minority Interest
0
0
0
0
0
0
1
2
3
1
Other Liabilities
1
4
9
9
3
11
17
37
70
195
Total Liabilities
2
N/A
11
+354%
24
+121%
32
+31%
36
+14%
22
-38%
341
+1 423%
711
+108%
810
+14%
1 091
+35%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
Retained Earnings
14
250
387
499
595
662
1 615
1 962
2 379
2 962
Additional Paid In Capital
71
607
681
718
741
783
1 495
1 720
1 931
2 375
Other Equity
0
0
0
0
0
0
0
0
0
0
Total Equity
58
N/A
356
+518%
293
-18%
219
-25%
146
-33%
121
-17%
120
N/A
242
-102%
447
-85%
587
-31%
Total Liabilities & Equity
60
N/A
367
+511%
318
-13%
250
-21%
182
-27%
143
-21%
221
+55%
469
+112%
362
-23%
504
+39%
Shares Outstanding
Common Shares Outstanding
61
81
82
79
79
99
382
398
421
671

See Also

Summary
IBRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IBRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IBRX stock valuation using valuation multiples.
Wall Street Estimates
IBRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IBRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 141,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.